Pill combos may stretch supply of flu vaccine

Share this article:
Philadelphia-based Hemispherx Biopharma says its experimental drug Ampligen, when mixed with Tamiflu, could help ease the shortage of the Roche antiviral.
Hemispherx chief executive William Carter told CNN/Money that creating an Ampligen-Tamiflu blend could either triple the strength of Tamiflu to a single patient or give three times as many patients access to the antiviral without losing potency.
Ampligen (dsRNA) has not been clinically tested to help combat avian flu but recently completed Phase III testing in patients with chronic fatigue syndrome. The report comes
as global demand for Tamiflu is far outstripping supply, with anxiety over a potential bird flu pandemic mounting.
Hemispherx's Carter is not the only one who believes he has found a way to stretch existing antiviral supply. Experts said probenecid, a generic pill for treating gout, also may increase the strength of Tamiflu if they are taken together. The journal Nature reported Tuesday that, in
a 2002 study, Roche scientists showed that Tamiflu concentrations in patients' blood were far higher when combined with probenecid, because probenecid blocks the excretion in urine of Tamiflu's active ingredient. While health officials cautioned that more study is needed before any recommendations can be made based on the data, some doctorshave said probenecid could help cut the cost of stockpiling Tamiflu.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.